MedPal AI plc (LSE:MPAL) has taken another significant step towards transforming digital healthcare with its acquisition of eMARx, completing what the company describes as its Health OS for the UK care home sector. The acquisition brings together prescribing, pharmacy fulfilment, medication administration and patient data into a single integrated platform, positioning MedPal AI to capitalise on one of the fastest-growing opportunities in healthcare technology.
Speaking on The Watchlist, Chief Executive Officer Jason Drummond explained that the acquisition represents far more than adding another software business. Instead, it completes a fully connected healthcare ecosystem designed to improve patient outcomes while creating a scalable, recurring revenue model.
“eMARx was the missing piece,” Drummond said. “We can now see the entire patient journey from the moment a GP issues a prescription, through robotic dispensing and delivery, right to the point where medication is administered to the resident.”
Addressing a Major Healthcare Challenge
The UK care home market represents a substantial opportunity, with approximately 16,500 care homes and more than 500,000 registered residents. According to Drummond, NHS England spent around £21 billion on medicines during 2025, with over £10 billion allocated to primary care, highlighting the scale of the market MedPal AI is targeting.
The company’s strategy aims to modernise a process that has historically relied on local community pharmacies by replacing fragmented systems with a centralised, technology-driven model.
MedPal AI’s pharmacy infrastructure combines advanced robotics with AI-powered software, creating an end-to-end solution capable of tracking medication throughout the entire supply chain. The addition of eMARx, which manages electronic medication administration within care homes, enables complete visibility from prescription through to patient administration.
Improving Care Through Connected Technology
For Drummond, the project also has a personal dimension.
He explained that his own experience supporting his mother, who lives with dementia in a care home, highlighted how difficult it can be for families to understand and monitor a loved one’s medication. That experience helped shape MedPal AI’s vision of making healthcare information more transparent and accessible for both care providers and families.
The integrated platform has the potential to significantly reduce medication errors, while providing greater confidence for carers, clinicians and relatives alike.
A Powerful Commercial Model
Alongside its clinical benefits, the acquisition strengthens MedPal AI’s commercial proposition.
Drummond confirmed that eMARx is already a profitable and growing business, bringing an established customer base and recurring software revenues to the group.
By combining the software platform with MedPal AI’s pharmacy services, the company can offer a more compelling proposition to care homes while increasing customer lifetime value.
The integrated offering also creates opportunities to bundle pharmacy supply with the eMARx platform, allowing MedPal AI to offer attractive commercial incentives while expanding recurring revenues across both software subscriptions and pharmacy fulfilment.
Technology Designed to Reduce Medication Errors
Medication errors remain a significant challenge across the care sector.
Drummond highlighted NHS estimates suggesting that around 250,000 hospital admissions each year involve care home residents, with 35–40% considered avoidable due to medication errors or inappropriate medicines management.
MedPal AI believes its combination of highly accurate robotic dispensing and the eMARx medication administration platform can play a meaningful role in reducing those avoidable incidents by improving accuracy, visibility and accountability throughout the medication journey.
Building the Healthcare Operating System
With the acquisition of eMARx, MedPal AI has moved closer to delivering its vision of a fully integrated Health OS for care homes.
Rather than operating as a traditional pharmacy provider, the company is building a technology-led platform that combines AI, pharmacy infrastructure, robotics and software into a single connected ecosystem.
As demand grows for more efficient, data-driven healthcare solutions, MedPal AI’s integrated approach positions the company to benefit from both expanding digital healthcare adoption and the increasing need for scalable care home services. By unifying software, pharmacy operations and patient data, the business is creating a platform designed to improve outcomes for residents while establishing multiple recurring revenue streams that could support long-term growth.
For more information visit – https://medpal.co/
Leave a Reply